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Faculty of Pharmacy, Medical University, Soﬁa, BulgariaA B S T R A C TBackground: Hyperphosphatemia is associated with signiﬁcant path-
ophysiology in chronic kidney disease (CKD). Control of hyperphos-
phatemia in patients with stage 3 to 5D CKD is now regarded as a high
priority. Objective: The primary purpose of this study was to perform
an economic analysis of the newly available treatments sevelamer
carbonate (SC) and lanthanum carbonate (LC) for the treatment of
hyperphosphatemia in patients not on dialysis in Bulgaria. Methods:
Both treatment options demonstrate equal efﬁcacy in controlling
hyperphosphatemia, as well as having a similar safety proﬁle in regard
to adverse effects. To differentiate between them, a cost-minimization
analysis was performed. A time period of 4 years was chosen to
perform a budget impact analysis. The robustness of the results was
tested through sensitivity analysis using Tornado diagrams. Results:
The estimated cost per patient per year with SC and LC would beee front matter Copyright & 2015, International S
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ndence to: Martin Petrov,Faculty of Pharmacy, 2 D€1441.75 and €1569.50, respectively, at the weighted average daily dose
regimen of 4000 mg SC and 2000 mg LC, whereas the cost would be
€2306.80 and €2354.25 for 6400 mg SC and 3000 mg LC, respectively.
Expected cost savings (discounted) for the 4-year period of the analysis
can reach between €1,363,601 and €2,727,201 at 4000 mg SC and 2000
mg LC dose regimen, whereas these can reach between €506,480 and
€1,012,961 at 6400 mg SC and 3000 mg LC, respectively. Conclusions:
The equal efﬁcacy, similar adverse effect proﬁle, and lower cost of SC
when used for the treatment of hyperphosphatemia in patients with
CKD not on dialysis should make it a preferred alternative.
Keywords: cost-minimization, hyperphosphatemia, lanthanum
carbonate, patients not on dialysis, sevelamer.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic kidney disease (CKD), the progressive deterioration of
kidney function, affects approximately 5% to 10% of the world’s
population [1]. It is most often caused by diabetes and hyper-
tension, which together account for approximately two-third of
CKD cases [2]. Similar numbers were reported for the Bulgarian
population [3]. Compared with the general population, patients
with CKD are at an increased risk of vascular calciﬁcation and
mineral and bone disorders, leading to an increased risk of
cardiovascular disease and mortality [1,4,5]. The sequel of min-
eral and bone disorders that accompany CKD has been termed
chronic kidney disease-mineral and bone disorder. It is a sys-
temic disorder of mineral and bone metabolism that occurs early
in the pathophysiology of CKD, when loss of kidney function
leads to progressive deterioration of the balance of minerals such
as phosphorus and calcium, hormones, and other metabolites.
Hyperphosphatemia or elevated phosphorus level in the blood is
common in patients with CKD-mineral and bone disorder and
independently and signiﬁcantly contributes to morbidity andmortality in these patients [1,4–8]. Decrease in the glomerular
ﬁltration rate below 59 ml/min is classiﬁed as mild to moderate
loss of kidney function, whereas that below 29 ml/min is
classiﬁed as severe according to Levin et al. [4]. Hyperphospha-
temia leads to increased risk of calciﬁcation [5], 70% increased
risk of starting dialysis [7,9], a 30% greater risk of cardiovascular
events [10,11], and increased risk of all-cause and cardiovascular-
related mortality [11–13]. Early and aggressive management of
mineral imbalance, especially phosphorus, is a priority for
patients with CKD and can achieve signiﬁcant savings to health
authorities by decreasing hospitalization rates within patients
with higher serum phosphate. Managing serum phosphorus in
CKD can lead to a decrease of 25% in the rate of cardiovascular
events, 4 times lesser mortality,as the risk of starting dialysis and
transplantation is reduced by 70% [7,9,14–17]. The goal of phos-
phorus management is to maintain levels within the normal
range of 2.5 to 4.5 mg/dL (0.81–1.45 mmol/L) according to the
Kidney Disease: Improving Global Outcomes guideline [1].
Phosphate binders are an essential component of managing
hyperphosphatemia. Treatment with phosphate binders isociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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improved overall survival in patients with CKD [18]. Traditional
binders such as those containing calcium or heavy metals are
effective at reducing serum phosphorus, but they pose health
risks associated with the accumulation of calcium or metal in the
body [19].
For part of the patients with CKD not on dialysis not eligible
for calcium- or other metal-based phosphate binders because of
vascular calciﬁcations and toxicity, new alternatives were
included in the positive list in Bulgaria, but these are still not
marketed effectively in the country—Renvela 800 mg  180
tablets (sevelamer carbonate [SC]; Genzyme, BV, The Nether-
lands) and Fosrenol 1000 mg  90 tablets (lanthanum carbonate
[LC]; Shire, Ltd., UK).
Renvela (SC) is a second-generation sevelamer (polymeric
amine) compound with the same active moiety and mechanism
of action as its predecessor Renagel (sevelamer hydrochloride
[SH]). SC differs from SH only in the replacement of chloride with
carbonate as the counterion, which serves to increase buffering
capacity and reduce the risk of gastrointestinal (GI) adverse
events (AEs) and acidosis related to decreased serum bicarbonate
concentrations. Such improvements in the chemical structure of
SC may reduce the need for monitoring chloride and bicarbonate
levels and may reduce the risk of acidosis [20].
In three head-to-head randomized studies, SC and SH were
shown to provide equivalent serum phosphorus control [21–23].
Given their structural similarities and equivalence in terms of
serum phosphorus control and safety, it is reasonable to expect
that SC will demonstrate an impact on other clinical outcomes
(e.g., calciﬁcation and mortality) that is similar to that of SH.
Both SC and LC are signiﬁcantly reducing serum phosphorus
in patients with CKD. They are well tolerated, where the pre-
dominant AEs are of a GI nature with no serious events [21–29].
In light of the increased incidence of CKD, constantly increas-
ing health care spending, and cost-containment policies con-
cerning medicines, there is a rising need for better allocation
of scarce resources through informed decisions from the
stakeholders.
We sought to investigate the evidence for efﬁcacy and safety
and to compare the direct cost of SC and LC in the treatment of
hyperphosphatemia in patients with CKD not on dialysis in
Bulgaria from the health authority perspective, that is, the
National Health Insurance Fund (NHIF). Another study objective
was to investigate the budget impact both products would have
on entering the market effectively.Methods
Search Strategy
A comprehensive search to identify all relevant studies was
carried out. PubMed, Scopus, The Cochrane Library, NHC Evi-
dence Search, and Google Scholar were searched (1998–August
2014). The following key words and phrases were used: seve-
lamer, lanthanum carbonate, clinical trial/study or efﬁcacy or
safety, hyperphosphatemia, cost-effectiveness, and cost-
minimization.
Selection Criteria
Each potentially relevant study was independently assessed by
two reviewers for inclusion in the study. For assessing the
efﬁcacy and safety, studies meeting the following criteria were
eligible for inclusion: controlled clinical trials in which the
efﬁcacy and safety are examined in adults, with prevalence of
white ethnicity (450%), with end-stage renal disease or patientswith CKD not on dialysis treated with SC, SH, and LC compared
with any phosphate binder or placebo.Type of Analysis and Study Perspective
The two studies that concern patients not on dialysis allow for an
indirect comparison [24,28], with SH being the common arm for
the indirect comparison of SC and LC. The indirect comparison
provides a similar AE proﬁle and efﬁcacy in controlling phosphate
levels in patients with CKD not on dialysis, justifying a cost-
minimization analysis (CMA).
As per approved label in Bulgaria, both SC and LC can be used
for the treatment of hyperphosphatemia in patients with CKD
not on dialysis, the cost of which is reimbursed at 75% by the
NHIF. For this reason, the present study was carried out from the
payer perspective.Cost-Minimization Analysis
Both medicines are administered orally, with no considerable
differences within the AEs’ proﬁles, which can lead to hospital-
ization and/or increase in treatment cost. CMA was performed
using the direct cost, that is, only unit cost per tablet of SC and LC
incurred from the NHIF.
The prices were retrieved online from the ofﬁcially published
registries on the National Council for Pricing & Reimbursement’s
Web site [30]. An exchange rate of 1,95,583 BGN for €1 was used.
The daily/yearly costs of both therapies were calculated using
the weighted average dose regimens, under which it was
assumed that meaningful clinical outcomes will be achieved,
that is, 4000 mg of SC versus 2000 mg of LC and 6400 mg of SC
versus 3000 mg of LC, respectively [31,32].Forecasting the Budget Impact to the NHIF
The budget impact was fulﬁlled for a 4-year period (2015–2018).
We explored three scenarios in which the patient’s allocation
between the two treatment options SC and LC was 100:0, 50:50,
and 0:100.
The budget impact model is prevalence based. The target
population was calculated by using the prevalence of CKD in
Bulgaria [3] within the population according to the last census
2011 [33].
Data regarding the prevalence considered for this analysis
were obtained from the national representative epidemiological
study of endocrine and kidney diseases in Bulgaria [3].
Patients eligible for treatment are those in CKD stage 3 to 4
who cannot be treated with calcium- and other metal-based
phosphate binders because of vascular calciﬁcation and toxicity.
Following the data published on the NHIF Web site, Intercon-
tinental Marketing Services (IMS) data for the market share, and
market trends when a new product is launched in Bulgaria, as
well as the cost-containment rules limiting the number of eligible
patients, we made several assumptions: An increase of 0.2% per year, corresponding to the prevalence
of CKD among the overall population within stage 3 to 4, as
well as a 0.2% yearly increase in the number of patients
eligible for treatment with SC and LC. Having in mind the very restrictive insurance policy, it is also
assumed that treatment will be received from 20% of the
eligible patients in 2015 as for 2016, 2017 and 2018, the
coverage will be 45%; 65% and 80% respectively.
The discount rate used was 3.5% as per National Institute of
Health and Care Excellence recommendations [34].
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A one-way sensitivity analysis (SA) was performed to examine
the changes in costs when key cost driver variables were varied.
The analysis includes the extreme values (30%) of the preva-
lence of stage 3 to 4 CKD in patients and the unit costs to whet
the attention to those of them with greatest effects on the results
of this analysis. The SA was performed with discounted costs
only. The results were presented under Tornado diagrams to
provide a quick overview and to represent the related importance
of the key cost driver variables.Results
The efﬁcacy and safety results of the clinical trials have been
published in detail elsewhere [21–29,35], and the relevant clinical
outcomes are summarized in Tables 1 and 2.
We found four clinical trials in which the efﬁcacy and safety
of SC were investigated in patients with CKD on dialysis [21–25]
and one clinical trial in patients not on dialysis [24].
Three clinical trials in which the efﬁcacy and safety of LC were
investigated in patients with CKD on dialysis were found [26–29]
and one clinical trial in patients not on dialysis [28].
Only one clinical trial was identiﬁed in which SH was directly
compared with LC in a head-to-head study in patients on dialysis
[35].
All three studies [21–23] in which the efﬁcacy and safety of SC
versus SH are compared in head-to-head trials in patients on
dialysis conﬁrm that both have equal efﬁcacy in lowering serum
phosphorus levels because the results are statistically signiﬁcant
(P o 0.001). Safety proﬁles were shown to be similar. AEs mainly
had a GI origin, with no serious AEs arising from both treatments,
because no clinically signiﬁcant changes were observed for safety
parameters.
In the study conducted by Ketteler et al. [24], SC shows
efﬁcacy in lowering serum phosphorus levels in patients with
CKD not on dialysis (P o 0.001), AEs were predominately mild to
moderate and were related to the GI tract in nature, and there
were no serious AEs or deaths occurring during the study that
were considered to be related to treatment.
LC also shows efﬁcacy in the treatment of hyperphosphate-
mia in patients on dialysis [26,27,29], with statistically signiﬁcant
results. The AEs predominantly had their origin in the GI tract
and had mild to moderate severity.
In the study of Sprague et al. [28], LC shows efﬁcacy in treating
hypophosphatemia in patients with CKD not on dialysis, with
statistically signiﬁcant difference (P o 0.02).
We found only one head-to-head clinical trial in which SH
was compared directly with LC in patients on dialysis. In this
open-label, randomized, crossover study (N ¼ 182), patients with
levels of serum phosphorus and calcium greater than 6.0 mg/dL
and 8.4 mg/dL, respectively, were randomized to receive either LC
or SH following washout. After 4 weeks of treatment and a
second washout period, patients switched to the alternative
treatment for 4 weeks. At the end of the two study periods,
serum phosphorus levels were reduced in patients treated with
LC by 1.7  0.1 mg/dL versus 1.4  0.1 mg/dL in patients treated
by SH. The difference of 0.3 mg/dL greater reduction observed
with LC after 4 weeks of treatment was not statistically signiﬁ-
cant (P ¼ 0.133). In a predeﬁned secondary analysis of patients
who completed 4 weeks of treatment with both binders, the
difference reached statistical signiﬁcance (mean difference –0.5
mg/dL; P ¼ 0.007). Serum calcium level was increased with LC (0.1
 0.1 mg/dL) and decreased with SH (–0.1  0.1 mg/dL; signiﬁcant
difference between treatments, P ¼ 0.02), and intact parathyroid
hormone levels were increased by a similar degree with boththerapies (LC 296.1  16.5 pg/mL; SH 286.9  16.4 pg/mL). Study
withdrawal was not different among the LC (n ¼ 25) and SH (n ¼
23) treatment groups, and GI-related AEs were observed in both
treatment groups (18.2% and 22.3%, respectively).Cost-Minimization Analysis
The unit cost (per tablet) used in the analysis was €0.79 for SC
and €2.15 for LC, calculated on the basis of the retail prices
reimbursed by the NHIF.
Because SC and LC have different potency in decreasing
phosphorus levels, their effects depend on the applied dose,
and it is important to deﬁne the relative dose for cost estimations
to be precise and to address what happens in the real settings.
Based on the head-to-head trial by Sprague et. al 2009 [35],
approved labels, and the recently published study of the dose
relativity of SC versus LC [36], the equi-effective doses reported as
similar are 2.1:1 (SC:LC).
Having in mind the equi-effective dose ratio and approved
labels, it was assumed that meaningful clinical outcomes will be
achieved with dose regimens of 4000 mg of SC versus 2000 mg of
LC and 6400 mg of SC versus 3000 mg of LC.
The data summarized in Table 3 represent the daily and
yearly costs incurred by the NHIF per patient treated with SC
and LC, respectively, and the expected cost savings within
proposed dose regimens.
Therefore, treatment with SC instead of LC will result in
a cost saving of €127.75 versus €47.45 per patient per year,
respectively.Forecasting the Budget Impact to the NHIF
The results of eligible patients for treatment with SC and LC in
Bulgaria are presented in Table 4.
The results of the budget impact are presented in Tables 5
and 6.
Table 5 presents the results of cost estimates and the savings
concerning the weighted average dose regimens of 4000 mg of SC
versus 2000 mg of LC.
Expected cost saving can reach as much as €1,507,769
(€1,363,601 discounted at 3.5%) at the patient allocation of SC
50%:LC 50% and €3,015,539 (€2,727,201) at the patient allocation of
SC 100% versus LC 100%, respectively.
Table 6 presents the results of cost estimates and savings
concerning the weighted average dose regimens of 6400 mg of SC
versus 3000 mg of LC.
Expected cost saving to the NHIF can reach as much as
€560,029 (€506,480) at the patient allocation of SC 50%:LC 50%
and €1,120,057 (€1,012,961) at the patient allocation of SC 100%
versus LC 100%, respectively.Sensitivity Analysis
The results of the one-way SA (discounted) clearly show that the
major cost drivers in the treatment of hyperphosphatemia in
patients with CKD not on dialysis are the unit costs of SC and LC.
Figures 1 and 2 summarize the most important results of SA
(discounted) under Tornado diagrams for 4000 mg SC versus 2000
mg LC dose regimens.
The results were conﬁrmed when the same values for the
prevalence of CKD and stage 3 to 4 of CKD and the unit costs of SC
and LC within 6400 mg SC versus 3000 mg LC dose regimens
were used.
Table 1 – Summary of the efﬁcacy and safety outcomes of SC (Renvela) investigations.
Study Renvela (SC): Patients
with CKD not on dialysis
Renvela (SC): Patients with CKD on dialysis
Ketteler et al.
[24]: Phase III,
multicenter, open-label,
single-arm dose-titration
study (N ¼ 49)
Delmez et al. [23]: Randomized,
double-blind, crossover study
(N ¼ 79)
Fan et al. [22]: Multicenter,
open-label, randomized, crossover
design study
(N ¼ 31)
Chen et al. [25]: Randomized,
double-blind, dose-titration study
(N ¼ 205)
Fishbane et al. [21]: Randomized,
open-label, parallel-design study
(N ¼ 213)
Efﬁcacy
results
related to
serum
phosphorus
Serum phosphorus levels
were reduced
signiﬁcantly from
baseline with Renvela
(MD, –1.4  1.0 mg/dL;
P o 0.001)
The mean serum phosphorus
was 4.6  0.9 mg/dL during
sevelamer carbonate
treatment and 4.7  0.9 mg/dL
during sevelamer
hydrochloride treatment. The
geometric least square mean
ratio (sevelamer carbonate/
sevelamer hydrochloride)
was 0.99 with a
corresponding 90% CI of 0.95
– 1.03, indicating that
sevelamer carbonate and
sevelamer hydrochloride are
equivalent in controlling
serum phosphorus.
The mean serum phosphorus was
1.6 ± 0.5 mmol/L (5.0 ± 1.5 mg/dL)
during sevelamer carbonate
powder treatment and 1.7 ± 0.4
mmol/L (5.2 ± 1.1 mg/dL) during
sevelamer hydrochloride tablet
treatment. Sevelamer carbonate
powder and sevelamer
hydrochloride tablets are
equivalent in controlling serum
phosphorus; the geometric least
square mean ratio was 0.95 (90%
CI 0.87–1.03).
Serum phosphorus levels decreased
signiﬁcantly in patients treated
with SC (change –0.69  0.64
mmol/L
[–2.14  1.98 mg/dL]) but
remained persistently elevated
with placebo (change –0.06  0.57
mmol/L
[–0.19  1.76 mg/dL]) (P o 0.0001)
Serum phosphorus levels were
reduced signiﬁcantly from
baseline with both Renvela (MD –
2.0  1.8 mg/dL;
P o 0.001) and Renagel
(MD –2.9  1.3 mg/dL; P o 0.001)
Key safety
results
AEs were predominately
mild to moderate and
were related to the GI
tract in nature
No SAEs or deaths occurred
during the study that
were considered to be
related to treatment
AEs were predominately related to
the GI tract in nature
A larger percentage of treatment-
related upper GI tract events
were reported with Renagel
(35.9%) than with Renvela
(20.5%):
-Diarrhea: Renvela, 2.7% vs.
Renagel, 6.4%
-Nausea: Renvela, 9.6% vs.
Renagel, 12.8%
-Vomiting: Renvela, 8.2% vs.
Renagel, 10.3%
-Constipation: Renvela, 0% vs.
Renagel, 3.8%
-Dyspepsia: Renvela, 1.4% vs.
Renagel, 3.8%
-Gastroesophageal reﬂux disease:
Renvela, 1.4% vs. Renagel, 5.1%
-Abdominal pain: Renvela, 2.7% vs.
Renagel, 1.3%
No SAEs were considered related to
either study treatment
No clinically signiﬁcant changes
were observed for safety
parameters
Mean serum bicarbonate levels
were increased signiﬁcantly (MD
þ1.3 mEq/L; P o 0.001) during
treatment with Renvela but not
with Renagel (P o 0.001)
Nine Renagel-related AEs (n ¼ 7) were
reported, including dyspepsia,
abdominal distension, abdominal
pain, diarrhea, gastritis, nausea, and
stomach discomfort
Four Renvela-related AEs (n ¼ 3) were
reported, including nausea and
vomiting in one patient, nausea
in one patient, and constipation
in one patient
The two patients who experienced
nausea and vomiting withdrew from
the study because of these events
No SAEs were considered related
to either study treatment
No patients died during either
treatment period
Serum bicarbonate levels were
increased signiﬁcantly with Renvela
vs. with Renagel
(P ¼ 0.001)
SC was well tolerated with 96%
adherence compared with 97%
adherence in the placebo arm.
Overall, AEs experienced by patients
in the SC and placebo treatment
groups were similar and consistent
with their underlying renal disease:
-GI disorders: placebo 11.4% vs.
Renvela 17%
-Constipation: placebo 0% vs.
Renvela 7.45
-Abdominal discomfort: placebo
5.7% vs. Renvela 3.0%
-Abdominal distension: placebo
1.4% vs. Renvela 4.4%
-Nausea: placebo 5.7% vs.
Renvela 0%
An expected increase in serum
bicarbonate level was noted
in the SC group
The overall percentage of patients who
experienced at least one treatment-
emergent AE was similar (Renvela
30.5% vs. Renagel 18.1%) between
treatment groups and consistent
with patients’ underlying renal
diseases
A larger percentage of treatment-
related upper GI tract events were
reported with Renvela (22.7%) vs.
With Renagel (11.1%):
-Diarrhea: Renvela 8.5% vs.
Renagel 5.6%
-Nausea: Renvela 9.9% vs. Renagel 2.8%
-Vomiting: Renvela 5.7% vs.
Renagel 1.4%
-Constipation: Renvela 0.7% vs.
Renagel 5.6%
4.3% of Renvela-treated patients
experienced oral administration
complications vs. no Renagel-
treated patients
No clinically signiﬁcant changes were
observed for safety laboratory
parameters in either
treatment group
Serum chloride level increased
signiﬁcantly and serum bicarbonate
level decreased signiﬁcantly with
Renagel; serum chloride and
bicarbonate levels remained
unchanged with Renvela treatment
AE, adverse event; CI, conﬁdence interval; CKD, chronic kidney disease; GI, gastrointestinal; GLSM, XXXX; MD, mean difference; SAE, serious adverse event; SC, sevelamer carbonate.
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Table 2 – Summary of efﬁcacy and safety outcomes for LC (Fosrenol) investigations.
Study (N) Fosrenol (LC): patients with CKD
not on dialysis
Fosrenol (LC): Patients with CKD on dialysis
Sprague et al. [28]: Phase 2,
randomized, double-blind, placebo-
controlled trial evaluating the
efﬁcacy and safety of LC in patients
with CKD stages 3 and 4 (N ¼ 121)
Hutchison et al. [27]: Efﬁcacy, tolerability,
and safety of LC in hyperphosphatemia: a
6-mo, randomized, comparative trial vs.
calcium carbonate (N ¼ 767)
Joy and Finn [26]: Randomized,
double-blind, placebo-controlled,
dose-titration, phase III study
(N ¼ 126)
Finn et al. [29]: Randomized,
double-blind clinical trial (N ¼ 145)
Efﬁcacy
results
related to
serum
phosphorus
Overall, this study demonstrated that LC is an
effective phosphate binder in patients with
CKD stages 3 and 4, with a safety proﬁle
and tolerability similar to that of placebo.
In patients with CKD stages 3 and 4, LC
treatment resulted in a statistically
signiﬁcant difference between groups in
change from baseline to end of treatment
for serum phosphorus (P ¼ 0.02), intact PTH
(P ¼ 0.02), and urinary phosphorus
excretion (P ¼ 0.04). A greater percentage of
patients achieved the target serum
phosphorus level of r4.6 mg/dL in the LC
group
Similar mean  SD serum phosphate levels were
seen in LC- and calcium carbonate–treated
patients at baseline: 8.28  2.05 mg/dL (2.67 
0.66 mmol/L) and 8.34  1.95 mg/dL (2.69  0.63
mmol/L), respectively. At the end of 5 wk of dose
titration, these values had decreased to 5.79 
1.61 mg/dL (1.87  0.52 mmol/L) in the LC group
and 5.15  1.49 mg/dL (1.66  0.48 mmol/L) in the
calcium carbonate group. After 17 wk of
treatment, LC was associated with a signiﬁcantly
greater decrease in calcium  phosphate product,
compared with calcium carbonate (P ¼ 0.009). A
trend toward reduced calcium phosphate product
was maintained at 25 weeks (p = 0.061).
At the study end point, the mean difference
in serum phosphorus levels between the
LC and placebo treatment arms was 1.91
mg/dL (0.62 mmol/L) (P o 0.0001).
Calcium  phosphorus product (P o
0.0001) and serum PTH levels (P o 0.01)
were also signiﬁcantly lower with LC vs.
placebo
After 6 wk of treatment, phosphorus levels
were signiﬁcantly lower in the
lanthanum groups receiving 1350 mg/d
and 2250 mg/d, compared with the
placebo group. Respective changes from
randomization were as follows: –0.95 
1.39 mg/dL (–0.31  0.45 mmol/L), –1.13 
2.01 mg/dL (–0.36  0.65 mmol/L), 0.75 
1.47 mg/dL (0.24  0.47 mmol/L) (P o
0.001). Signiﬁcant reductions in serum
phosphorus, compared with placebo,
occurred in the lanthanum 1350 mg/d
group from the second week of
treatment and in the 2250 mg/d group
from the ﬁrst week of treatment
Key safety
results
AEs were experienced by 47.4% of the patients
in the LC group compared with 61.0% in
the placebo group. These were mainly
gastrointestinal in nature, with nausea (LC
and placebo 9.0% and 9.8%, respectively)
and vomiting (6.4% and 2.4%, respectively)
being the most common. In total, 19.3% of
the AEs experienced in the LC group were
considered related to treatment, compared
with 16.7% in the placebo group
Most AEs were of mild or moderate severity in both
LC- and calcium carbonate–treated patients
during the titration and maintenance phases;
o10% of the AEs were classiﬁed as severe. GI AEs
were reported most frequently and occurred with
similar frequency in the two treatment groups:
Constipation: LC 6% vs. placebo 6.7%
The incidence of drug-related AEs was
similar between placebo- and LC-treated
patients
AEs were related mainly to the GI tract (e.g.,
nausea and vomiting)
Diarrhea: 12.6% vs. 9.7%
Nausea: 15.9% vs. 12.7%
Vomiting: 18.4% vs. 11.2%
AEs were predominately mild to moderate
and were related to the GI tract in nature
Treatment-related AEs occurred in 39% of
the patients treated with LC and 44% of
the placebo group
AE, adverse event; CKD, chronic kidney disease; GI, gastrointestinal; LC, lanthanum carbonate; PTH, parathyroid hormone.
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Table 3 – Cost savings to the NHIF per patient per year under the two treatment regimens.
Treatment option Weighted average dose
regimen*
Cost of one
tablet to the
NHIF (€)
Cost per day
per patient to
the NHIF (€)
Cost per year
per patient to
the NHIF (€)
Renvela 800 mg  180 ﬁlm-
coated tablets
4000 mg (5 tablets  800 mg) 0.79 3.95 1441.75
Fosrenol 1000 mg  90
chewable tablets
2000 mg (2 tablets  1000 mg) 2.15 4.30 1569.50
Expected cost savings to the NHIF per patient per year –127.75
Renvela 800 mg  180 ﬁlm-
coated tablets
6400 mg (8 tablets  800 mg) 0.79 6.32 2306.80
Fosrenol 1000 mg  90
chewable tablets
3000 mg (3 tablets  1000 mg) 2.15 6.45 2354.25
Expected cost savings to the NHIF per patient per year –47.45
NHIF, National Health Insurance Fund.
* Where the dose is not exactly within the equi-effective dose of 2.1:1, it was set to the closest number of tablets.
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SC and LC are widely used and are effective and safe for the
treatment of hyperphosphatemia. Despite of the limited utiliza-
tion, we choose a CMA on the basis of results from a head-to-
head trial [30] and because of the lack of a statistically signiﬁcant
difference between both treatment options in terms of efﬁcacy
and safety.
However, it should be noted that there were a couple of
limitations, which should be taken into consideration:T
a
P
O
P
P
P
P
P
E
E
P
N
C
*
†Currently, there is just one available clinical trial reﬂecting the
study selection criteria that directly compares SH versus LC
because patients explored were in end-stage renal disease but
not ones not on dialysis. CMA compares only the direct costs under the assumption that
the clinical outcomes and AE proﬁles of both are equivalent.
Some researchers could consider the use of CMA as a limi-
tation, but for health care systems with very limited budgets it is
important for such analysis to be performed. Bulgaria has one ofable 4 – Overall population, prevalence of CKD, eligible
nalysis.
opulation data
verall population (n)*
opulation growth per year (%)*
revalence of CKD (%)†
atients with CKD (n)
revalence of CKD stages 3–4 (%)†
atients with CKD stages 3–4 eligible for any phosphate binder (n)
ligible patients for treatment with SC and LC, from all patients in stage
CKD (%)
ligible patients for treatment with SC and LC, from all patients in stage
CKD (n)
ercentage of patients covered from all eligible for SC or LC treatment (%
umber of patients covered from all eligible for SC or LC treatment ¼ N
patients included in the analysis
KD, chronic kidney disease; LC, lanthanum carbonate; NSI, National St
Data retrieved from Bulgarian NSI databases [33].
Data from national representative survey for endocrine and kidney disthe lowest expenditures as part of GDP for health care within
European Union, 4.8% versus the average for EU of 7.5% from the
gross domestic product. Statistical information published on the
Eurostat Web site clearly shows that the health care expenditure
in Bulgaria for the period 2002 to 2012 has decreased from 5.3% to
4.8% [37] and for 2014 it was 4.85% [38]. This shows that stringent
control over the expenditures is imposed and choice of the less
costly but equally effective alternatives will beneﬁt the patients.
The expenses for CKD and dialysis treatment are about €37
million per year. Expenses are steady within the local NHIF
budget for last 3 years, with no change for 2015 [38].
The cost difference between both regimens was only due to
the lower registered price for SC. Our interest in that study was
provoked by the inclusion of both products in the positive list.
Despite the fact that SC and LC have registered prices, both
products were not marketed during the study period. That is why
we developed three versions of the budget impact analysis, assum-
ing the market shares to be 100%/0%, 50%/50%, and 0%/100%.
The percentage of eligible patients covered by the NHIF, that
is, 20% in 2015 to 80% in 2018, was assumed on the basis of the
current market trends and prescription criteria for the treatment
of CKD [39].patients, and the number of patients included in the
2015 2016 2017 2018
7,305,653 7,196,068 7,066,538 6,925,207
–0.80 –1.50 –1.80 –2.00
12.89 13.09 13.29 13.49
941,699 941,966 939,143 934,211
5.31 5.51 5.71 5.91
50,005 51,902 53,625 55,212
s 3–4 of 20.0 20.5 21.0 21.5
s 3–4 of 10,001 10,640 11,261 11,871
) 20 45 65 80
umber of 2000 4788 7320 9497
atistical Institute; SC, sevelamer carbonate.
eases in Bulgaria [3].
Table 5 – Costs incurred by the NHIF for the 4-y period at 4000 mg SC vs. 2000 mg LC dose regimens with
expected cost savings.
Scenario 1.1. Patients allocation: SC 100% vs. LC 0% of eligible patients
SC Patients Cost per patient per year at 4000 mg weighted
average dose (€)
Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
Year 1 2000 1441.75 2,883,500 2,883,500
Year 2 4788 1441.75 6,903,099 6,444,117
Year 3 7320 1441.75 10,553,610 9,518,752
Year 4 9497 1441.75 13,692,300 11,932,048
Total costs 34,032,509 30,778,417
Scenario 1.2. Patients allocation: SC 50% vs. LC 50% of eligible patients
SC Patients Cost per patient per year at 4000 mg weighted
average dose (€)
Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
Year 1 1000 1441.75 1,441,750 1,441,750
Year 2 2394 1441.75 3,451,550 3,222,058
Year 3 3660 1441.75 5,276,805 4,759,376
Year 4 4749 1441.75 6,846,150 5,966,024
Total costs SC 17,016,254 15,389,208
LC Patients Cost per patient per year at 2000 mg weighted
average dose (€)
Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
Year 1 1000 1569.50 1,569,500 1,569,500
Year 2 2394 1569.50 3,757,383 3,507,557
Year 3 3660 1569.50 5,744,370 5,181,093
Year 4 4749 1569.50 7,452,771 6,494,659
Total costs LC 18,524,024 16,752,809
Scenario 1.3. Patients allocation: SC 0% vs. LC 100% of eligible patients
LC Patients Cost per patient per year at 2000 mg weighted
average dose (€)
Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
Year 1 2000 1569.50 3,139,000 3,139,000
Year 2 4788 1569.50 7,514,766 7,015,114
Year 3 7320 1569.50 11,488,740 10,362,185
Year 4 9497 1569.50 14,905,542 12,989,318
Total costs 37,048,048 33,505,618
Total costs for the 4-y period
Scenarios Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
SC 100% 34,032,509 30,778,417
SC 50% vs. LC 50% 35,540,278 32,142,017
LC 100% 37,048,048 33,505,618
Total cost difference for the 4-y period
Scenario Costs (not discounted) (€) Costs (discounted at 3.5%) (€) Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
vs. SC 50% vs. LC 50% SC 50% vs. LC 50% LC 100% LC 100%
SC 100% –1,507,769 –1,363,601 –3,015,539 –2,727,201
LC, lanthanum carbonate; NHIF, National Health Insurance Fund; SC, sevelamer carbonate.
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patients are in stage 3 to 4 of CKD, most will be on low-protein
diet and with phosphorus levels close to the recommended ones,
and so the most suitable and preferred regimen seems to be 4000
mg SC versus 2000 mg LC.
The results in this analysis are derived under the assumption
that the dose relativity of SC:LC is 2.1:1 [36]. In two other studies,the dose relativity was estimated to be 2.8:1 and 2.7:1, respec-
tively [40,41], but the results in both were derived by
using indirect comparison of trials that are widely variable
clinically, which made the calculation of the equi-effective dose
uncertain.
The SA results show that the unit cost outweigh the CKD
prevalence. From both tornado diagrams, it is obvious that the
Table 6 – Costs incurred by the NHIF for the 4-y period at 6400 mg SC vs. 3000 mg LC dose regimens.
Scenario 1.1. Patients allocation: SC 100% vs. LC 0% of eligible patients
SC Patients Cost per patient per year at 6400 mg weighted
average dose (€)
Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
Year 1 2000 2306.80 4,613,600 4,613,600
Year 2 4788 2306.80 11,044,958 10,310,587
Year 3 7320 2306.80 16,885,776 15,230,002
Year 4 9497 2306.80 21,907,680 19,091,277
Total costs 54,452,014 49,245,466
Scenario 1.2. Patients allocation: SC 50% vs. LC 50% of eligible patients
SC Patients Cost per patient per year at 6400 mg weighted
average dose (€)
Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
Year 1 1000 2306.80 2,306,800 2,306,800
Year 2 2394 2306.80 5,522,479 5,155,293
Year 3 3660 2306.80 8,442,888 7,615,001
Year 4 4749 2306.80 10,953,840 9,545,639
Total costs SC 27,226,007 24,622,733
LC Patients Cost per patient per year at 3000 mg weighted
average dose (€)
Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
Year 1 1000 2354.25 2,354,250 2,354,250
Year 2 2394 2354.25 5,636,075 5,261,336
Year 3 3660 2354.25 8,616,555 7,771,639
Year 4 4749 2354.25 11,179,156 9,741,989
Total costs LC 27,786,036 25,129,214
Scenario 1.3. Patients allocation: SC 0% vs. LC 100% of eligible patients
LC Patients Cost per patient per year at 3000 mg weighted
average dose (€)
Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
Year 1 2000 2354.25 4,708,500 4,708,500
Year 2 4788 2354.25 11,272,149 10,522,672
Year 3 7320 2354.25 17,233,110 15,543,278
Year 4 9497 2354.25 22,358,312 19,483,977
Total costs 55,572,071 50,258,427
Total costs for the 4-y period
Scenario Costs
(not discounted) (€)
Costs
(discounted at 3.5%) (€)
SC 100% 54,452,014 49,245,466
SC 50% vs. LC 50% 55,012,043 49,751,947
LC 100% 55,572,071 50,258,427
Total cost difference for the 4-y period
Scenario Costs (€) Costs (discounted at 3.5%) (€) Costs (€) Costs
(discounted at 3.5%) (€)
vs. SC 50% vs. LC 50% SC 50% vs. LC 50% LC 100% LC 100%
SC 100% –560,029 –506,480 –1,120,057 –1,012,961
LC, lanthanum carbonate; NHIF, National Health Insurance Fund; SC, sevelamer carbonate.
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change in the savings. The second conclusion that could be
drawn from the SA is that the change in the savings depends
on the prevalence of the disease in stage 3 to 4. This has a higher
impact in the change in the savings than does the variation in the
prevalence of CKD at all.
In the context of the scarce resources available for health care,
the aging population, the increased prevalence of chronicdiseases, the cost-containment policies, and the efforts of the
government to provide treatment to a wider group of patients, it
is becoming more important that decision makers take into
consideration data from such analyses. This will add more
reasoning to informed decision making about the usage of given
treatment options and their economic implications.
This analysis represents the ﬁrst study to evaluate the
economic impact of drug selection in the case of treatment of
Fig. 1 – Tornado diagram presenting the changes in cost savings when individual parameter values are varied (4000 mg SC vs.
2000 mg LC dose regimens for patient allocation SC 100% vs. SC 50%:LC 50%). LC, lanthanum carbonate; SC, sevelamer carbonate.
Fig. 2 – Tornado diagram presenting the changes in cost savings when individual parameter values are varied (4000 mg SC vs.
2000 mg LC dose regimens for patient allocation SC 100% vs. LC 100%). LC, lanthanum carbonate; SC, sevelamer carbonate.
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and LC in Bulgaria.Conclusions
This economic analysis has shown that SC is associated with
lower costs compared with LC when used for the treatment of
hyperphosphatemia in patients with CKD not on dialysis.
For decision makers with limited budgets, the treatment with
SC regimen therefore represents an efﬁcient use of resources for
patients with CKD not on dialysis in Bulgaria.
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